Henrikki Santti
Specialist in Urology
I am a Specialist in Urology. My special expertise is prostate cancer, and I have over 15 years of experience in its diagnostics, treatments, follow-up, and supporting quality of life. I also gladly treat urinary symptoms and erectile dysfunction.
My goal is to offer you a thorough assessment and an unhurried encounter, so that we can choose the treatment option best suited to your situation. During the appointment, we will clearly go through the examination results and findings, and you will have time for questions. If necessary, I will discuss your situation multidisciplinarily with an oncologist and a radiologist.
Welcome to my practice – your loved ones are also welcome to join. You can also book a remote appointment, but for the first appointment, I often recommend a face-to-face meeting.
Languages
Finnish, English
Education
Fellow of the EBU (FEBU), European Board of Urology 2011
Specialist in Urology, University of Helsinki 2010
Doctor of Medicine, University of Helsinki 2004
Licentiate of Medicine, University of Helsinki 1998
Work history
- Docrates Mehiläinen Cancer Center, specialist 2026-
- Mehiläinen, National Head Physician of Urology 2019-
- Docrates Cancer Center, specialist 2016-2018
- Mehiläinen, specialist 2011-
- HUS Urology, specialist 2010-
- HUS Urology, Resident Physician in Urology 2008-2010
- South Karelia Central Hospital, Resident Physician in Surgery 2004-2008
Memberships and positions of trust
Member and Treasurer of the Finnish Urological Association
Member of the European Association of Urology
Member of the Finnish Surgical Association
Member of the Finnish Endocrine Society
Scientific activities
My doctoral dissertation, published in 2004, focused on the mechanisms of action of male hormones, i.e., androgens. Since then, my research has broadly focused on prostate cancer, specifically prostate cancer screening, diagnostics, treatment selection, monitoring of treatment outcomes, and quality of life after treatments. I have participated in international clinical trials concerning hormonal drug therapy for prostate cancer.